search
Back to results

Complete Health Improvement Program for Geisinger Health Plan Members With Type 2 Diabetes (CHIP-RCT)

Primary Purpose

Type 2 Diabetes

Status
Not yet recruiting
Phase
Not Applicable
Locations
Study Type
Interventional
Intervention
CHIP Program
Usual Care
Sponsored by
Thomas Morland
About
Eligibility
Locations
Arms
Outcomes
Full info

About this trial

This is an interventional other trial for Type 2 Diabetes focused on measuring Type 2 Diabetes

Eligibility Criteria

18 Years - undefined (Adult, Older Adult)All SexesDoes not accept healthy volunteers

Inclusion Criteria:

  • Geisinger Health Plan member for a full year prior to enrollment in the study, with plans to remain covered for a full year after the first study visit
  • HbA1c resulted within a year of enrollment in the study
  • ≥ 18 years
  • Current type 2 diabetes diagnosis
  • Living in the five-county region served by the Miller Center (Lycoming, Montour, Northumberland, Snyder and Union) with the ability to arrange their own transportation to the Miller Center in Lewisburg at least 10 times in a 3-month period
  • Access to computer, phone, or tablet with sufficient internet to complete program activities.

Exclusion Criteria:

  • Presence of medical condition requiring specific diet (e.g., Celiac disease, phenylketonuria)
  • Presence of medical condition contraindicating participation in CHIP, as determined by the Principal Investigator (e.g. cancer on active treatment)
  • Pregnancy or plan to become pregnant within one year
  • Inability to give informed consent due to mental or psychiatric impairment
  • Participation in the Fresh Food Farmacy program

Sites / Locations

    Arms of the Study

    Arm 1

    Arm 2

    Arm Type

    Active Comparator

    Active Comparator

    Arm Label

    CHIP Program

    Usual Diabetes Care

    Arm Description

    GHP members randomized to the intervention arm will participate in the CHIP Program.

    GHP members assigned to the control arm will receive the routine standard of care for GHP members.

    Outcomes

    Primary Outcome Measures

    Change in HbA1c
    Change in HbA1c percentage at 6 months compared to baseline
    Percentage of patients who complete the study
    What percentage of individuals contacted agree to participate; what percentage of individuals contacted are excluded from the study based on lack of access to transportation or Internet; what percentage of participants enrolled complete the intervention?

    Secondary Outcome Measures

    HbA1c control at 3 months
    Change in HbA1c percentage at 3 months compared to at baseline
    LDL-C at 3 and 6 months
    Change in LDL-C levels at 3 and 6 months compared to baseline
    Biometrics at 3 and 6 months
    Change in weight, body mass index, blood pressure at 3 and 6 months compared to baseline
    Psychosocial/behavioral at 3 and 6 months
    Change in Wellbeing360 survey at 3 and 6 months compared to baseline
    Health behaviors, as measured by CHIP participation
    Overall program completion, attendance stratified by in-person versus online, proportion of required in-person attended
    Number of diabetes medications prescribed at 3 and 6 months
    Change in number of diabetes medications at 3 and 6 months compared to baseline
    Total cost of care over 6 months.
    Change in total cost of care at 6 months compared to baseline

    Full Information

    First Posted
    May 20, 2021
    Last Updated
    March 3, 2022
    Sponsor
    Thomas Morland
    search

    1. Study Identification

    Unique Protocol Identification Number
    NCT04924400
    Brief Title
    Complete Health Improvement Program for Geisinger Health Plan Members With Type 2 Diabetes
    Acronym
    CHIP-RCT
    Official Title
    Complete Health Improvement Program to Improve Glycemic Control and Reduce Cost of Care for Geisinger Health Plan Members With Type 2 Diabetes
    Study Type
    Interventional

    2. Study Status

    Record Verification Date
    March 2022
    Overall Recruitment Status
    Not yet recruiting
    Study Start Date
    March 2022 (Anticipated)
    Primary Completion Date
    June 2022 (Anticipated)
    Study Completion Date
    December 2022 (Anticipated)

    3. Sponsor/Collaborators

    Responsible Party, by Official Title
    Sponsor-Investigator
    Name of the Sponsor
    Thomas Morland

    4. Oversight

    Studies a U.S. FDA-regulated Drug Product
    No
    Studies a U.S. FDA-regulated Device Product
    No
    Data Monitoring Committee
    No

    5. Study Description

    Brief Summary
    The Complete Health Improvement Program (CHIP) is a lifestyle improvement program intended to prevent and/or manage cardiovascular disease, diabetes, and other health conditions. This is a pilot-scale randomized-controlled trial comparing the clinical, utilization, and financial outcomes of adult health plan members with type 2 diabetes mellitus (T2DM) offered CHIP versus those only offered standard health plan coverage. We hypothesize that Geisinger Health Plan (GHP) members with T2DM offered CHIP in addition to standard insurance coverage will have improvement in HbA1c and improvements in other biometrics, biomarkers, psychometrics and utilization/financial outcomes, including LDL-C, systolic blood pressure, body mass index, waist circumference, number of diabetes medications prescribed, Wellbeing360 survey, and total cost of healthcare.
    Detailed Description
    This is a pilot prospective randomized-controlled trial of 60 patients randomized to either the intervention group; in which patients enroll in the CHIP program, or the control group, in which patients follow their usual diabetes care. We hypothesize that Geisinger Health Plan members with T2DM offered CHIP in addition to standard insurance coverage will have improvement in HbA1c and improvements in other biometrics, biomarkers, psychometrics and utilization/financial outcomes, including LDL-C, systolic blood pressure, body mass index, waist circumference, number of diabetes medications prescribed, Wellbeing360 survey, and total cost of healthcare. The intervention group will attend 18 classes covering topics such as diet, sleep, exercise instruction, stress management, and toxic substance avoidance. Biometrics (weight, BMI, waist circumference, systolic/diastolic blood pressure), biomarkers (HbA1c, LDL-C) and psychometrics (Wellbeing 360 survey) will be collected on all participants at baseline, 3-months and 6-months. The CHIP curriculum will be administered during twice weekly 1-hour classes over a 6-week period, followed by weekly 1-hour classes for an additional 6 weeks. The protocol will begin with a 1-month in-person period, with participants subsequently offered the choice between in-person and online attendance for the remaining sessions. The primary aim is to compare change in HbA1c, LDL-C, systolic blood pressure, body mass index, and waist circumference for GHP members offered CHIP versus members offered standard insurance coverage at 3- and 6-months. Through this pilot study, we hope to gain insight into whether and how such an application of CHIP could be a cost-effective tool for health plans such as GHP to achieve clinical and financial goals for adult members with T2DM.

    6. Conditions and Keywords

    Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
    Type 2 Diabetes
    Keywords
    Type 2 Diabetes

    7. Study Design

    Primary Purpose
    Other
    Study Phase
    Not Applicable
    Interventional Study Model
    Parallel Assignment
    Masking
    None (Open Label)
    Allocation
    Randomized
    Enrollment
    60 (Anticipated)

    8. Arms, Groups, and Interventions

    Arm Title
    CHIP Program
    Arm Type
    Active Comparator
    Arm Description
    GHP members randomized to the intervention arm will participate in the CHIP Program.
    Arm Title
    Usual Diabetes Care
    Arm Type
    Active Comparator
    Arm Description
    GHP members assigned to the control arm will receive the routine standard of care for GHP members.
    Intervention Type
    Behavioral
    Intervention Name(s)
    CHIP Program
    Intervention Description
    GHP members randomized to the intervention arm will participate in the following activities: Attend 2 group meetings per week over 6 weeks, followed by one group meeting per week for 6 weeks (12 weeks total); each meeting will last about one hour. CHIP classes for weeks 1-4 and week 12 require in-person attendance, while week 5-11 classes can be attended either virtually or in-person. Receive a copy of The Optimal Diet, The Official CHIP Cookbook. The following data will be collected at weeks 1,12 and 26: Biometrics: weight, BMI, waist circumference, systolic and diastolic blood pressure Biomarkers (blood tests): HbA1c, LDL-C Psychometrics: Wellbeing360 survey
    Intervention Type
    Behavioral
    Intervention Name(s)
    Usual Care
    Intervention Description
    GHP members assigned to the control arm will receive the routine standard of care for GHP members. Members will receive a summary of diabetes-related benefits available to members with type 2 diabetes. The following data will be collected at weeks 1,12 and 26: Biometrics: Weight, BMI, waist circumference, systolic and diastolic blood pressure Biomarkers (blood tests): HbA1c, LDL-C Psychometrics: Wellbeing360 survey
    Primary Outcome Measure Information:
    Title
    Change in HbA1c
    Description
    Change in HbA1c percentage at 6 months compared to baseline
    Time Frame
    6 months
    Title
    Percentage of patients who complete the study
    Description
    What percentage of individuals contacted agree to participate; what percentage of individuals contacted are excluded from the study based on lack of access to transportation or Internet; what percentage of participants enrolled complete the intervention?
    Time Frame
    6 months
    Secondary Outcome Measure Information:
    Title
    HbA1c control at 3 months
    Description
    Change in HbA1c percentage at 3 months compared to at baseline
    Time Frame
    3 months
    Title
    LDL-C at 3 and 6 months
    Description
    Change in LDL-C levels at 3 and 6 months compared to baseline
    Time Frame
    3 and 6 months
    Title
    Biometrics at 3 and 6 months
    Description
    Change in weight, body mass index, blood pressure at 3 and 6 months compared to baseline
    Time Frame
    3 and 6 months
    Title
    Psychosocial/behavioral at 3 and 6 months
    Description
    Change in Wellbeing360 survey at 3 and 6 months compared to baseline
    Time Frame
    3 and 6 months
    Title
    Health behaviors, as measured by CHIP participation
    Description
    Overall program completion, attendance stratified by in-person versus online, proportion of required in-person attended
    Time Frame
    6 months
    Title
    Number of diabetes medications prescribed at 3 and 6 months
    Description
    Change in number of diabetes medications at 3 and 6 months compared to baseline
    Time Frame
    3 and 6 months
    Title
    Total cost of care over 6 months.
    Description
    Change in total cost of care at 6 months compared to baseline
    Time Frame
    6 months

    10. Eligibility

    Sex
    All
    Minimum Age & Unit of Time
    18 Years
    Accepts Healthy Volunteers
    No
    Eligibility Criteria
    Inclusion Criteria: Geisinger Health Plan member for a full year prior to enrollment in the study, with plans to remain covered for a full year after the first study visit HbA1c resulted within a year of enrollment in the study ≥ 18 years Current type 2 diabetes diagnosis Living in the five-county region served by the Miller Center (Lycoming, Montour, Northumberland, Snyder and Union) with the ability to arrange their own transportation to the Miller Center in Lewisburg at least 10 times in a 3-month period Access to computer, phone, or tablet with sufficient internet to complete program activities. Exclusion Criteria: Presence of medical condition requiring specific diet (e.g., Celiac disease, phenylketonuria) Presence of medical condition contraindicating participation in CHIP, as determined by the Principal Investigator (e.g. cancer on active treatment) Pregnancy or plan to become pregnant within one year Inability to give informed consent due to mental or psychiatric impairment Participation in the Fresh Food Farmacy program
    Central Contact Person:
    First Name & Middle Initial & Last Name or Official Title & Degree
    Thomas B Morland, MD
    Phone
    570-214-5025
    Email
    tmorland@geisinger.edu
    First Name & Middle Initial & Last Name or Official Title & Degree
    Avery M Schulze, MPH
    Phone
    570-214-4215
    Email
    amschulze@geisinger.edu
    Overall Study Officials:
    First Name & Middle Initial & Last Name & Degree
    Thomas B Morland, MD
    Organizational Affiliation
    Geisinger Clinic
    Official's Role
    Principal Investigator

    12. IPD Sharing Statement

    Plan to Share IPD
    No

    Learn more about this trial

    Complete Health Improvement Program for Geisinger Health Plan Members With Type 2 Diabetes

    We'll reach out to this number within 24 hrs